Ardelyx, Inc. presents its Q4 and full-year 2025 earnings call slide deck, highlighting strong performance across core products despite a wider net loss.370
Key Financial Results
Q4 revenue reaches $125.25 million, marking a 7.9% increase year-over-year and surpassing analyst expectations by $7.21 million. IBSRELA generates $86.6 million in the quarter, reflecting 61% growth from the prior year period.2223
Full-year revenue climbs to $407.3 million, driven by IBSRELA sales of $274.2 million, up 73% annually. The company reports a net loss of $61.6 million for 2025, compared to $39.1 million in 2024.2420
Earnings per share stands at $0.00, slightly missing estimates of $0.01.37
2026 Guidance and Outlook
Ardelyx projects product revenue between $520 million and $550 million for 2026, signaling continued expansion in IBSRELA and XPHOZAH markets.24
Business Momentum
IBSRELA demonstrates accelerating adoption for irritable bowel syndrome with constipation, while XPHOZAH supports hyperphosphatemia treatment. The presentation underscores pipeline progress and commercial strategies to drive future growth.32
